Search results for "predictive factor"

showing 10 items of 30 documents

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by (18)FDG-PET/CT

2017

Abstract Objectives The objective of this study was to investigate fludeoxyglucose F 18 positron emission tomography/computed tomography ( 18 FDG-PET/CT) parameters as predictive of response after stereotactic ablative radiotherapy (SABR) for lung oligometastases. Methods The inclusion criteria of the current retrospective study were as follows: (1) lung oligometastases treated by SABR, (2) presence of 18 FDG-PET/CT before and after SABR for at least two subsequent evaluations, (3) Karnofsky performance status higher than 80, and (4) life expectancy longer than 6 months. All patients were treated with a biologically equivalent dose of at least 100 Gy with an alpha/beta ratio of 10. The foll…

MaleFludeoxyglucose F-18Lung Neoplasmsmedicine.medical_treatment18FDG-PET/CT; Lung malignancies; Predictive factors; SABR; Adenocarcinoma; Aged; Aged 80 and over; Carcinoma Non-Small-Cell Lung; Carcinoma Squamous Cell; Female; Fluorodeoxyglucose F18; Follow-Up Studies; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Recurrence Local; Neoplasm Staging; Positron Emission Tomography Computed Tomography; Prognosis; Radiopharmaceuticals; Retrospective Studies; Tumor Burden; Radiosurgery; Oncology; Pulmonary and Respiratory MedicineSABR volatility model030218 nuclear medicine & medical imaging0302 clinical medicinePositron Emission Tomography Computed TomographyAblative case80 and overMedicineNon-Small-Cell LungSABRmedicine.diagnostic_test(18)FDG-PET/CTMiddle AgedPrognosisTumor Burdenmedicine.anatomical_structureLocalOncologyPositron emission tomography030220 oncology & carcinogenesisLymphatic MetastasisFemaleRadiologyPredictive factorsPulmonary and Respiratory Medicinemedicine.medical_specialtyLung malignanciesStandardized uptake value18FDG-PET/CTAdenocarcinomaRadiosurgery03 medical and health sciencesFluorodeoxyglucose F18HumansAgedNeoplasm StagingRetrospective StudiesLungbusiness.industryCarcinomaRetrospective cohort studyRadiation therapyNeoplasm RecurrenceSquamous CellRadiopharmaceuticalsbusinessNuclear medicineFollow-Up Studies(18)FDG-PET/CT; Lung malignancies; Predictive factors; SABR
researchProduct

EAU Guidelines on Vesicoureteral Reflux in Children

2012

Context: Primary vesicoureteral reflux (VUR) is a common congenital urinary tract abnormality in children. There is considerable controversy regarding its management. Preservation of kidney function is the main goal of treatment, which necessitates identification of patients requiring early intervention.Objective: To present a management approach for VUR based on early risk assessment.Evidence acquisition: A literature search was performed and the data reviewed. From selected papers, data were extracted and analyzed with a focus on risk stratification. The authors recognize that there are limited high-level data on which to base unequivocal recommendations, necessitating a revisiting of thi…

MalePediatricsACID SCINTIGRAPHYmedicine.medical_treatmentKidneyurologic and male genital diseasesPediatricsVOIDING CYSTOURETHROGRAPHYURETERAL REIMPLANTATIONMedicineAntibiotic prophylaxisFamily historyChildChildrenNEONATAL HYDRONEPHROSISReimplantationUrinary tract infectionVesicoureteral refluxDiagnostic Techniques Urologicalfemale genital diseases and pregnancy complicationsAnti-Bacterial AgentsTreatment OutcomeRenal scarringBulking agentsEAUPREDICTIVE FACTORSChild PreschoolPredictive value of testsUrologic Surgical ProceduresFemaleRisk assessmentmedicine.medical_specialtyUrologyUrinary systemContext (language use)GuidelinesVesicoureteral refluxURINARY-TRACT-INFECTIONANTIBIOTIC-PROPHYLAXISPredictive Value of TestsHumansWatchful WaitingVesico-Ureteral RefluxProphylaxisbusiness.industryInfantEndoscopymedicine.diseaseVURSurgeryISOLATED ANTENATAL HYDRONEPHROSISEarly DiagnosisRENAL DAMAGESPONTANEOUS RESOLUTIONLaparoscopybusinessWatchful waitingEuropean Urology
researchProduct

Predictive Factors of Abdominal Compartment Syndrome in Neonatal Age

2014

In the pediatric population, abdominal compartment syndrome (ACS) is a known complication of abdominal wall defect repair. However, there are only few reports on ACS in newborns and only a proposal of critical intra-abdominal pressure value (IAP) in term newborns, absent in preterm newborns. Although the prevalent clinical sign is tense abdominal distension, it may be difficult to distinguish ACS from pathologies that will not require decompression. The purpose of this study was to identify predictors for ACS and therefore morbidity or mortality indicators. We reviewed newborns presenting with tense abdominal distension and end organ failure. Anamnestic, clinical, laboratory, and instrument…

MalePediatricsmedicine.medical_specialtyNeonatal intensive care unitAbdominal compartment syndromePopulationGestational AgeAbdominal wallSettore MED/38 - Pediatria Generale E SpecialisticaIntubation IntratrachealHumansMedicineLactic AcideducationAbdominal Compartment Syndrome Predictive Factors in Neonatal AgeRetrospective Studieseducation.field_of_studybusiness.industryIncidenceAbdominal wall defectAbdominal WallInfant NewbornObstetrics and GynecologyGestational ageAbdominal distensionmedicine.diseaseRespiration ArtificialSurgerymedicine.anatomical_structureCase-Control StudiesPediatrics Perinatology and Child HealthApgar ScoreFemaleIntra-Abdominal HypertensionIntra-Abdominal Hypertensionmedicine.symptombusinessAmerican Journal of Perinatology
researchProduct

Ventricular dysfunction and number of non compacted segments in non compaction: Non-independent predictors.

2010

Abstract Background Isolated ventricular noncompaction (IVNC) is characterized by multiple prominent trabeculations and deep intertrabecular recesses. Some reports prove that the chronic heart failure may occur in approximately half of the patients. In this report we investigate the correlation between the number of non compacted segments and entity of systolic dysfunction from the registry and subregistries of the SIEC. Method To identify the correlation between ventricular dysfunction and number of segments involved in non compaction we evaluated a consecutive series of 238 patients affected by non compaction, from the SIEC (Societa Italiana di Ecografia Cardiovascolare) registry. The ave…

Malemedicine.medical_specialtyAdolescentCardiomyopathyVentricular non compactionDiastoleCardiomyopathyProminent trabeculationsSeverity of Illness IndexNOVentricular Dysfunction LeftYoung AdultPredictive Value of TestsInternal medicinemedicineHumansRegistriesChildVentricular dysfunctionAgedVentricular non compaction; Cardiomyopathy; Ventricular dysfunction; Number of segments; Compact/spongy ratioAged 80 and overIsolated Noncompaction of the Ventricular Myocardiumbusiness.industryCompact/spongy ratioInfantMiddle Agedmedicine.diseaseNumero signPredictive factorSurgeryHeart failureChild PreschoolCardiologyNumber of segmentsFemaleMyocardial diseaseCardiology and Cardiovascular MedicinebusinessCardiomyopathy; Number of segments Compact/spongy ratio; Ventricular dysfunction; Ventricular non compactionHeart Failure Systolic
researchProduct

Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: Comparison of adalimumab, etanercept…

2012

Objective: To evaluate the risk of serious infections (SIs) in RA patients receiving anti-TNF therapy on the basis of the data included in the GISEA register. METHODS: The study involved 2769 adult patients with long-standing RA (mean age 53.2±13.4years; mean disease duration 9.0±8.3years) enrolled in the GISEA register, who had been treated for at least 6months with TNF inhibitors or had discontinued therapy due to SI: 837 (30%) treated with infliximab (IFN), 802 (29%) with adalimumab (ADA), and 1130 (41%) with etanercept (ETN). RESULTS: 176 patients had experienced at least one of the 226 Sis during the 9years of treatment with an anti-TNF agent, an overall incidence of 31.8/1000 patient-…

Malerheumatoid arthritisArthritisReceptors Tumor Necrosis FactorEtanerceptEtanerceptArthritis RheumatoidAdalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis FactorsRheumatoidadalimumabMonoclonalReceptorsImmunology and AllergyRegistriesinfectionsHumanizedAnti-TNF agents; GISEA register; Infections; Predictive factorsIncidence (epidemiology)IncidenceAntibodies MonoclonalAnti-TNF agentsMiddle AgedRheumatoid arthritisAntirheumatic AgentsCohortTumor Necrosis FactorsFemaleInfectionPredictive factorsmedicine.druganti-TNF; serious infections; rheumatoid arthritisAdultmedicine.medical_specialtyanti-TNF therapy; infections; rheumatoid arthritis; adalimumab; etanercept; infliximabanti-TNF therapyserious infectionsImmunologyInfections rheumatoid arthritis anti-TNF therapyAntibodies Monoclonal HumanizedInfectionsAntibodiesInternal medicinemedicineAdalimumabHumansAgedGISEA registerbusiness.industryArthritisAdalimumabanti-TNFGISEA register; Infections; Anti-TNF agents; Predictive factors; Adalimumab; Adult; Aged; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Antirheumatic Agents; Arthritis Rheumatoid; Etanercept; Female; Humans; Immunoglobulin G; Incidence; Infection; Infliximab; Male; Middle Aged; Receptors Tumor Necrosis Factor; Registries; Tumor Necrosis Factorsmedicine.diseaseInfliximabInfliximabConcomitantImmunoglobulin GImmunologyTumor Necrosis Factor InhibitorsbusinessTumor Necrosis Factorinfliximabetanercept
researchProduct

Correlation between classical prognostic factors and overexpression of HER2 and HER3 in localized gastric cancer

2012

e14589 Background: Although HER2 overexpression has been identified as a predictive factor for targeted therapy in advanced gastric cancer (GC), little is known about its role in localized GC. Recent studies suggest that not only HER2 but also HER3 might have a role in prognosis in GC. Our study aimed to identify the prevalence of HER2 and HER3 overexpression in a series of localized GC and to describe correlations of these with traditional prognostic factors Methods: We performed a retrospective analysis of HER2 and HER3 overexpression in archived tumour samples in pts diagnosed with GC at stage I-III. HER2 was assessed with herceptest, (negative if 0 or 1+, or positive with 2+ or 3+). St…

OncologyCancer Researchmedicine.medical_specialtybusiness.industrymedicine.medical_treatmentCancermedicine.diseaseHercepTestPredictive factorTargeted therapybody regionsCorrelationOncologyInternal medicinemedicineStatistical analysisStage (cooking)skin and connective tissue diseasesReceptorbusiness
researchProduct

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

2016

International audience; Background: To determine whether dose/volume specific endpoints (DVSE) or Area under the rectal DVH curve (rAUC) better predict acute gastrointestinal (GI) toxicity in prostate cancer patients treated with IMRT in the era of daily image guidance (IG-IMRT). Methods: A set of DVSE was recorded from V25 to V75 (increments of 5Gy) (both in % and in cc) for 180 men. The rAUC was calculated for doses ranging between 25Gy and 50Gy (rAUC(25-50)). Univariate and multivariate logistic regressions were performed to determine the relationship between DVSE or rAUC(25-50) and the appearance of any acute GI toxicity. Results: The rates of acute grade 1 (G1), G2 and G3 GI toxicities…

OncologyMale[SDV.IB.IMA]Life Sciences [q-bio]/Bioengineering/Imagingmedicine.medical_treatmentGastroenterology030218 nuclear medicine & medical imaging[ SDV.CAN ] Life Sciences [q-bio]/Cancer[ SDV.IB.MN ] Life Sciences [q-bio]/Bioengineering/Nuclear medicineProstate cancer0302 clinical medicineProstateLarge intestineConformal Radiation-Therapy[ SDV.IB.IMA ] Life Sciences [q-bio]/Bioengineering/ImagingAged 80 and overGastrointestinal tractProstate cancerRadiotherapy DosageMiddle Aged3. Good healthmedicine.anatomical_structureImpactOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisArea Under CurveToxicityImage Guidancemedicine.medical_specialtyRectum[SDV.CAN]Life Sciences [q-bio]/Cancer[SDV.IB.MN]Life Sciences [q-bio]/Bioengineering/Nuclear medicine03 medical and health sciencesInternal medicinemedicineBiochemical ControlHumansRadiology Nuclear Medicine and imagingRadiation InjuriesAgedRadiotherapybusiness.industryResearchRectumProstatic Neoplasmsmedicine.diseaseRadiation therapyAcute rectal toxicity predictive factorLogistic ModelsRadiotherapy Intensity-ModulatedbusinessAbsolute volumeRadiation Oncology (London, England)
researchProduct

Human equilibrative nucleoside transporter 1 (hENT1) levels predict response to gemcitabine in patients with biliary tract cancer (BTC)

2009

Background and aim: Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patients' outcome according to the expression of hENT1 in tumoral cells of patients receiving gemcitabine-based therapy. Materials and Methods: The immunohistochemistry analysis was performed on samples from thirty-one patients with unresectable biliary tract cancer (BTC) consecutively treated with first line gemcitabine-based regimens. Results: Positive hENT1 staining patients were…

Oncologymedicine.medical_specialtyPathologyCancer ResearchAntimetabolites Antineoplasticmedicine.medical_treatmentEquilibrative nucleoside transporter 1DeoxycytidineEquilibrative Nucleoside Transporter 1Statistical significanceInternal medicineDrug DiscoveryMedicineHumansHENT1PharmacologyChemotherapyUnivariate analysisPredictive markerBiliary tract cancer; Gemcitabine; HENT1; Predictive factor; Drug Discovery3003 Pharmaceutical Science; Pharmacology; Cancer Researchbiologybusiness.industryDrug Discovery3003 Pharmaceutical ScienceCancermedicine.diseaseImmunohistochemistryGemcitabineGemcitabineBiliary Tract NeoplasmsOncologybiology.proteinImmunohistochemistryBiliary tract cancerbusinessPredictive factormedicine.drug
researchProduct

Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib

2021

Background and Aim: Lenvatinib is a standard of care option in first-line therapy of advanced hepatocellular carcinoma (HCC). In the present study, we aim to identify, in patients with HCC treated with lenvatinib, a possible association between occurrence and grading of adverse events (AEs) and outcome. Methods: We performed a retrospective analysis of 606 Japanese and Italian patients treated with lenvatinib in first-line setting and investigated the possible correlation between the onset of AEs, toxicity grade (G) and outcome measures such as overall survival (OS) and progression-free survival (PFS). Results: The appearance of arterial hypertension G ≥ 2 independently predicted prolonged …

Phenylurea Compoundmedicine.medical_specialtyCarcinoma HepatocellularMultivariate analysispredictive factorsadverse eventlenvatinibGastroenterologypredictive factorchemistry.chemical_compoundQuality of lifeInternal medicinemedicineHumansAdverse effectRetrospective Studiesadverse events; hepatocellular carcinoma; lenvatinib; predictive factorsSettore MED/12 - GastroenterologiaHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsHazard ratiohepatocellular carcinomamedicine.diseaseadverse eventsConfidence intervalDiscontinuationchemistryLiver NeoplasmHepatocellular carcinomaQuality of LifeQuinolinesLenvatinibbusiness
researchProduct

The Long and Winding Road to Useful Predictive Factors for Anti-EGFR Therapy in Metastatic Colorectal Carcinoma: The KRAS/BRAF Pathway

2010

Monoclonal antibodies targeting the epidermal growth factor receptor (EGFR) have improved outcomes for patients with metastatic colorectal carcinoma. Among patients not carrying activating mutations in the KRAS gene, only a limited number will experience tumor response to these therapeutic agents. The role of BRAF mutations in determining resistance to this treatment is emerging through preclinical and clinical studies. Standardization and validation of laboratory mutation analysis is needed to allow an optimal use of anti-EGFR therapies in the management of colorectal carcinoma. Clinical single-arm and randomized studies were conducted both in first-line and refractory settings to evaluate…

Proto-Oncogene Proteins B-rafCancer ResearchPrognosiColorectal cancerCetuximabColorectal Neoplasmmedicine.disease_causeBRAFProto-Oncogene Proteins p21(ras)FOLFOXProto-Oncogene ProteinsAntineoplastic Combined Chemotherapy ProtocolsKRASmedicineHumansPanitumumabEpidermal growth factor receptorBRAF; Cetuximab; Colorectal carcinoma; KRAS; Panitumumab; Predictive factors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Colorectal Neoplasms; Humans; Mutation; Prognosis; Proto-Oncogene Proteins; Proto-Oncogene Proteins B-raf; Receptor Epidermal Growth Factor; Signal Transduction; ras Proteins; Cancer Research; OncologyneoplasmsProto-Oncogene ProteinClinical Trials as TopicAntineoplastic Combined Chemotherapy ProtocolCetuximabbiologybusiness.industryPanitumumabGeneral Medicineras ProteinPrognosismedicine.diseasedigestive system diseasesOxaliplatinErbB ReceptorsColorectal carcinomaOncologyMutationras ProteinsCancer researchFOLFIRIbiology.proteinReceptor Epidermal Growth FactorKRASPredictive factorColorectal NeoplasmsbusinessHumanSignal Transductionmedicine.drugOncology
researchProduct